Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Amphastar Pharmaceuticals, Inc. AMPH
$41.72
+$0.04 (0.10%)
На 18:00, 12 мая 2023
-16.11%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
2027969856.00000000
-
week52high
44.15
-
week52low
26.76
-
Revenue
498987000
-
P/E TTM
19
-
Beta
0.76055300
-
EPS
1.69000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Capital One | Overweight | 29 июл 2022 г. | |
| Wells Fargo | Equal-Weight | Equal-Weight | 15 мар 2022 г. |
| Piper Sandler | Overweight | Overweight | 11 мар 2022 г. |
| Piper Sandler | Overweight | Neutral | 07 янв 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 17 мар 2021 г. |
| Piper Sandler | Overweight | Overweight | 25 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Petersen Floyd F. | D | 86108 | 500 | 01 февр 2023 г. |
| Petersen Floyd F. | D | 86608 | 500 | 03 янв 2023 г. |
| Petersen Floyd F. | D | 87108 | 500 | 01 дек 2022 г. |
| Petersen Floyd F. | D | 87608 | 500 | 01 ноя 2022 г. |
| Petersen Floyd F. | D | 88108 | 500 | 03 окт 2022 г. |
| Petersen Floyd F. | D | 88608 | 500 | 01 сент 2022 г. |
| PETERS WILLIAM J | D | 49522 | 10000 | 09 авг 2022 г. |
| PETERS WILLIAM J | D | 100480 | 10000 | 09 авг 2022 г. |
| PETERS WILLIAM J | A | 110480 | 10000 | 09 авг 2022 г. |
| Liawatidewi Yakob | D | 0 | 3055 | 09 авг 2022 г. |
Новостная лента
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 19:07
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.47 per share a year ago.
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
Accesswire
03 мая 2023 г. в 16:30
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 3, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2023 ended March 31, 2023, after the market closes on Tuesday, May 9, 2023, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
Zacks Investment Research
26 апр 2023 г. в 11:28
Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Eli Lilly to sell Baqsimi diabetes drug to Amphastar for around $1 billion
Proactive Investors
24 апр 2023 г. в 12:30
Eli Lilly and Co (NYSE:LLY) revealed that it will sell Baqsimi, its nasal treatment for severe hypoglycemia in people with diabetes, to Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for around $1 billion. The Indianapolis, Indiana-based company has signed a definitive agreement to divest Baqsimi worldwide to Amphastar for $500 million in cash at closing and an additional $125 million in cash upon the one-year anniversary of closing.
Eli Lilly to sell hypoglycemia treatment for up to $1.1 billion in cash and milestone payments to Amphastar
Market Watch
24 апр 2023 г. в 06:54
Shares of Eli Lilly & Co. LLY gained 0.5% in premarket trading Monday, after the drugmaker announced an agreement to sell its hypoglycemia treatment for people with diabetes Baqsimi to Amphastar Pharmaceuticals Inc. AMPH for up to $1.075 billion in cash and potential milestone payments. Under terms of the agreement, Amphastar will pay $500 million in cash upfront and another $125 million in cash one year after the deal closes, which is expected to occur in the third quarter of 2023.